Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Are Blood Plasma Treatments Due for a Revolution?

Dr Trevor Castor is the President of Aphios International, a name that means “virus-free” in Greek. “We are developing a pathogen-reduction technology called CFI to clear blood plasma, plasma products, biologics and medical devices of viruses and other pathogens. Our technology is unique in that it does not use heat, chemicals or radiation that could be harmful…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

Dr Trevor Castor is the President of Aphios International, a name that means “virus-free” in Greek.

“We are developing a pathogen-reduction technology called CFI to clear blood plasma, plasma products, biologics and medical devices of viruses and other pathogens.

Our technology is unique in that it does not use heat, chemicals or radiation that could be harmful to the underlying beneficial proteins, such as antibodies.

Our technology works by giving the virus the bends. [We put] virus particles with a gas under pressure, then quickly release the pressure, and the infected virus pops at the weakest points, very much like the disruption of a scuba diver who rises too rapidly or the popping of a balloon.

Our research, funded by the National Institutes of Health, has been successful, and we are [continually] raising funds.”

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Medicare sets $137.53 maximum add-on payment per eligible inpatient case for CT triage AI

Medicare sets $137.53 maximum add-on payment per eligible inpatient case for CT triage AI

Medicare has announced a maximum add-on payment of $137.53 per eligible inpatient case for the use of AI in CT triage, utilizing Aidoc’s CT Body triage technology. This move emphasizes the importance of workflow integration, governance, and coding in hospitals employing radiology AI. The new technology add-on payment (NTAP) signifies a clear investment in AI-driven healthcare solutions.

  • 01Medicare introduces a $137.53 per-case payment for AI in CT triage.
  • 02Hospitals must integrate AI with proper workflow, governance, and coding.
  • 03The NTAP reflects investment in radiology AI solutions.

Aug 30, 2026

Rasonque’s 13.2-month survival result is about to hit hospital formularies

Rasonque’s 13.2-month survival result is about to hit hospital formularies

FDA has cleared Revolution Medicines' drug Rasonque for treating metastatic pancreatic adenocarcinoma. Hospitals are now integrating this drug into their formularies, focusing on operations like pathways, genotyping, and specialty pharmacy flow.

  • 01Rasonque has received FDA clearance for treating metastatic pancreatic adenocarcinoma.
  • 02Hospitals are working on integrating Rasonque into their formularies.
  • 03Operational focus includes pathways, genotyping, and specialty pharmacy flow.

Aug 30, 2026

Real-time radiation dose tracking is moving from badges to live dashboards in procedure rooms

Real-time radiation dose tracking is moving from badges to live dashboards in procedure rooms

Radiation Detection Company has introduced a live radiation dose tracking system called Radiant that updates every 0.2 seconds. GE HealthCare has developed browser-based imaging access for hospitals, transforming how radiation monitoring is managed in procedure rooms. This advancement in live dashboards is enhancing real-time monitoring capabilities in healthcare facilities.

  • 01Radiation Detection Company's Radiant updates radiation dose data every 0.2 seconds.
  • 02GE HealthCare has developed browser-based imaging access for better hospital management.
  • 03Live dashboards are transforming radiation monitoring in procedure rooms.

Aug 30, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512